• 1
    Lithander A. Intracellular fluid of Way bread (Plantago major) as a prophylactic for mammary cancer in mice . Tumor Biol 1992;13:138 41.
  • 2
    Gaw HW & Wang HP. Survey of Chinese drugs for presence of antibacterial substances. Science 1949;110:11 2.
  • 3
    Obolentseva GV & Khadzhai YI. Pharmacological study of Plantaglucide (Plantago major leaf extract) used in the treatment of an acid gastritis and peptic ulcer. Farmakol Toksikol 1966;29:469 72 (English (Abstract)).
  • 4
    Yesilada E, Sezik E, Fujita T et al Screening of some Turkish mediconal plants for their antiularogenic activities. Phyt Res 1993;7:263 5.
  • 5
    Guillén MEN, Emim JAS, Souccar C et al Analgesic and anti-inflammatory activities of the aqueous extract of Plantago major L. Int J Pharmacognosy 1997;35:99 104.
  • 6
    Samuelsen AB, Paulsen BS, Wold JK et al Isolation and partial characterization of biologically-active polysaccharides from Plantago major L. Phytother Res 1995;9:211 8.
  • 7
    Samuelsen AB, Paulsen BS, Wold JK et al Characterization of a biologically active pectin from Plantago major L. Carbohyd Polymers 1996;30:37 44.
  • 8
    Samuelsen AB, Lund I, Djahromi JM et al Structural features and anti-complementary activity of some heteroxylan polysaccharide fractions from the seeds of Plantago major L. Carb Polymers 1999;38:133 43.
  • 9
    Nathan CF. Secretory products of macrophages. J Clin Invest 1987;79:319 26.
  • 10
    Breitman TR, Hemmi H, Imaizumi M. Induction by physiological agents of differentiation of the human leukemia cell line HL-60 to cells with functional characteristics. Prog Clin Biol Res 1986;226:215 33.
  • 11
    Wilson ME & Morrison DC. Evidence for different requirements in physical state for the interaction of lipopolysaccharides with the classical and alternative pathways of complement. Eur J Biochem 1982;128:137 41.
  • 12
    Henrichsen J. The pneumococcal typing system and pneumococcal surveillance. J Infection 1979;1 (Suppl.): 2:31 7.
  • 13
    Aaberge IS, Eng J, Lermark G et al Virulence of Streptococcus pneumoniae in mice: a standardized method for preparation and frozen storage of the experimental bacterial inoculum. Microb Pathogen 1995;18:141 52.
  • 14
    Reynolds JA, Kastello MD, Harrington DG et al Glucan-induced enhancement of host resistance to selected infectious diseases. Infect Immun 1980;30:51 7.
  • 15
    Hetland G, Løvik M, Wiker HG. Protective effect of β-glucan against mycobacterium bovis, BCG infection in Balb/c mice. Scand J Immunol 1998;47:548 53.
  • 16
    Hetland G, Ohno N, Aaberge IS, Løvik M. Protective effect of β-glucan against systemic Streptococcus pneumoniae infection in mice. FEMS Immunol Med Microbiol 2000;27:111 6.DOI: 10.1016/s0928-8244(99)00172-8
  • 17
    Samuelsen AB. Dr. Thesis: Polysaccharides in Plantago major L. Studies of structures and biological activity. University of of Oslo, Oslo, Norway 1998.
  • 18
    Steinsvik TE, Gaarder PI, Aaberge IS, Løvik M. Engraftment and humoral immunity in SCID and RAG-2-deficient mice transplanted with human peripheral blood lymphocytes. Scand J Immunol 1995;42:607 16.
  • 19
    Aaberge IS, Michaelsen TE, Rolstad AK et al SCID-Hu mice immunized with a pneumococcal vaccine produce specific human antibodies and show increased resistance to infection. Infect Immun 1992;60:4146 53.
  • 20
    Aaberge IS & Løvik M. The antibody response after immunization with pneumococcal polysaccharide vaccine in splenectomized mice: the effect of re-immunization with pneumococcal antigens. APMIS 1996;104:307 17.
  • 21
    Savedra R Jr, Delude RL, Ingalls RR et al Mycobacterial lipoarabinomannan recognition requires a receptor that shares components of the endotoxin signaling system. J Immunol 1996;157: 2549 54.
  • 22
    Rouleux-Bonnin F, Monsigny M, Legrand A. Transcriptional expression of mannose receptor gene during differentiation of human macrophages. Biochem Biophys Res Commun 1995; 217:106 12.DOI: 10.1006/bbrc.1995.2751
  • 23
    Vetvicka V, Thornton BP, Ross GS. Soluble β-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonizid target cells. J Clin Invest 1996;98:50 61.24.